Literature DB >> 15458432

Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice.

Anja S Mühlfeld1, Min W Spencer, Kelly L Hudkins, Elizabeth Kirk, Renee C LeBoeuf, Charles E Alpers.   

Abstract

INTRODUCTION: Reduction of renal mass is frequently associated with progressive loss of kidney function. We examined the effects of hyperlipidemia on renal pathology and mediators of tissue damage in B6.ROP Os/+ mice, a model of reduced renal mass.
METHODS: C57BL/6 control mice and B6.ROP Os/+ mice were fed normal rodent chow or a high fat, high cholesterol (HFHC) diet for 12 weeks. Kidney function and renal pathology were assessed.
RESULTS: Hyperlipidemia led to a decline in kidney function in C57BL/6 mice. Renal pathology was characterized by an increase in glomerular matrix and cellularity, glomerular and tubulointerstitial macrophage influx, and increased tubular epithelial cell turnover. Chow-fed B6.ROP Os/+ animals demonstrated glomerular hypertrophy with an increase in mesangial matrix and cellularity that was characterized by macrophage influx and increased proliferation. The tubulointerstitium showed increased macrophages as well as tubular atrophy and dilation. Renal pathology was accompanied by an increase in blood urea nitrogen (BUN) and proteinuria. Hyperlipidemia in B6.ROP Os/+ mice resulted in increased plasma BUN compared to chow-fed B6.ROP Os/+ animals and aggravated renal pathology by further increasing glomerular matrix and glomerular hypercellularity. Glomerular hypercellularity was associated with increased expression of platelet-derived growth factor-B (PDGF B) and its receptor beta. Glomerular transforming growth factor-beta (TGF-beta) mRNA expression was increased in B6.ROP Os/+ mice, hyperlipidemic C57BL/6 mice and hyperlipidemic B6.ROP Os/+ animals compared to controls and correlated with the amount of mesangial matrix.
CONCLUSION: This study demonstrates that hyperlipidemia worsens renal pathology in B6.ROP Os/+ mice with a decline in renal function mediated at least in part through increased renal expression of the cytokines PDGF B and TGF-beta.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15458432     DOI: 10.1111/j.1523-1755.2004.00854.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

1.  The effects of combined treatment with niacin and chromium on the renal tissues of hyperlipidemic rats.

Authors:  Meliha Sengezer Inceli; Sehnaz Bolkent; M Mutluhan Doger; Refiye Yanardag
Journal:  Mol Cell Biochem       Date:  2006-11-24       Impact factor: 3.396

Review 2.  Foam cells and the pathogenesis of kidney disease.

Authors:  Minseob Eom; Kelly L Hudkins; Charles E Alpers
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-05       Impact factor: 2.894

3.  Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice.

Authors:  Deepa Taneja; Joel Thompson; Patricia Wilson; Katie Brandewie; Liliana Schaefer; Bonnie Mitchell; Lisa R Tannock
Journal:  J Lipid Res       Date:  2010-01-28       Impact factor: 5.922

4.  Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy.

Authors:  Joel Thompson; Patricia Wilson; Katie Brandewie; Deepa Taneja; Liliana Schaefer; Bonnie Mitchell; Lisa R Tannock
Journal:  Am J Pathol       Date:  2011-06-30       Impact factor: 4.307

5.  IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus.

Authors:  Christophe Richez; Kei Yasuda; Ramon G Bonegio; Amanda A Watkins; Tamar Aprahamian; Patricia Busto; Rocco J Richards; Chih Long Liu; Regina Cheung; Paul J Utz; Ann Marshak-Rothstein; Ian R Rifkin
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

6.  Urinary exosomes: a novel means to non-invasively assess changes in renal gene and protein expression.

Authors:  Silvia Spanu; Claudia R C van Roeyen; Bernd Denecke; Jürgen Floege; Anja S Mühlfeld
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.